Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermatix
- Development stage
- Unknown
- Lead developer
- MEDA Pharma
- Administration
- Topical
01
Overview
Dermatix is a topical silicone gel used for the prevention and management of hypertrophic scars and keloids. It is primarily composed of polysiloxanes (silicone polymers), such as dimethicone. Classified as a medical device, it works by creating an occlusive barrier over the scar tissue, which increases hydration of the stratum corneum. This physical mechanism helps to soften and flatten scars, relieve itching and discomfort, and reduce redness. It was evaluated in a comparative study by University Hospital, Ghent to measure its occlusive and hydrating capacity relative to other silicone-based products.
- Brand names
- Dermatix
- Other names
- Dermatix UltraSilicone gelDermatix-University Hospital, Ghent
Beyond the preview
Go deeper on Dermatix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dermatix.